期刊文献+

NGR修饰的香豆素-6隐形脂质体的制备及其体外细胞摄取性质 被引量:11

Preparation of NGR-modified coumarin-6 containing stealth liposome and study on its in vitro cell uptake properties
原文传递
导出
摘要 目的:应用NGR导向磷脂化合物修饰香豆素-6隐形脂质体以构建肿瘤新生血管靶向载体。方法:合成NGR导向磷脂化合物并进行了表征。采用薄膜法制备了不同比例NGR修饰的香豆素-6隐形脂质体,以包封率和泄漏率为指标,考察其稳定性;以人脐静脉血管内皮细胞(HUVEC,阳性细胞,CD13高表达)为靶细胞,用流式细胞仪和激光共聚焦显微镜对载体体外细胞摄取性质进行了分析。结果:制得的不同比例NGR修饰的香豆素-6隐形脂质体的包封率均>90.0%,12 h的体外累积泄漏率<9.0%。NGR修饰后的香豆素-6隐形脂质体在HUVEC中的摄取率明显高于未经修饰的隐形脂质体,且以0.64%(摩尔比)的用量摄取效果最好,而人冠状动脉内皮细胞(HCAEC,阴性细胞,CD13无表达)对两者的摄取没有明显差异。激光共聚焦观察表明,脂质体摄取入胞后,香豆素-6主要分布在细胞质中。结论:NGR修饰的隐形脂质体能够实现血管内皮细胞靶向,且用量以0.64%摩尔比为最佳。 OBJECTIVE To prepare tumor angiogenesis targeting carrier by use of NGR-modified coumarin-6 containing stealth liposomes. METHODS NGR-oriented phospholipid compounds were synthesized and characterized. NGR-modified coumarin-6 containing stealth liposomes were prepared by thin film evaporation method. Encapsulation efficiency and leakage versus time profile were used as index to investigate the liposomal stability. Human umbilical vein endothelial cells (HUVEC, positive cell, high expression of CD13) were prepared as model ceils to evaluate uptake efficiency of liposomes by flow cytometry and confocal laser microscopy. RF^ULTS The mean encapsulation efficiency of NGR-modified coumarin-6 containing stealth liposomes was higher than 90. 0% and the in vitro cumulative leakage of NGR-modified coumarin-6 from liposomes were less than 9. 0 % in 12 h. HUVEC uptake rate of NGR-modified liposome was higher than unmodified liposomes, while there was no significant difference between the uptake rate of NGR-modified and unmodified liposomes in human coronary artery endothe- lial cells (HCAEC negative cell, no expression of CD13). Using confocal laser microscopy, coumarin-6 was found to be mainly distributed in cytoplasm following cellular uptake of NGR modified liposomes. CONCLUSION NGR modified stealth lipo- somes can be applied as vascular endothelial cell targeting carriers for the treatment of tumor. The optimum ratio of NGR DSPE-PEG2000 in lipid composition was 0. 64%.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第6期427-432,共6页 Chinese Journal of Hospital Pharmacy
基金 国家自然科学基金项目(编号:30701111 81001644) 广东省自然科学基金项目(编号:10451040701004643)
关键词 NGR 香豆素-6 隐形脂质体 HUVEC 主动靶向 eoumarin-6 stealth liposomes HUVEC active targeting
  • 相关文献

参考文献10

  • 1Santos AO,da Silva LC, Bimbo LM,et al. Design of peptidm targeted liposomes containing nucleic acids [J]. BBA-Biomem- branes, 2010,1798 (3) : 433-441.
  • 2Antcazk C, de Meester I, Bauvois B. Eetopeptidases in patho physiology [J]. Bioessays,2001,23(3) :251-260.
  • 3Carl-MeGrath S, I.endeckel U, Ehert M, et al. Ectopeptidases in rum our biology a review [J]. Histol Histopalhol, 2006,21 (12):1339- 1353.
  • 4Hashida H, Takabayashi A, Kanai M, et al. Aminopetidase N is involved in cell motiltiy and angiogenesis: its clinical signifi eance in human clone cancer [J]. Gastroenterology, 2001,122(2) :376 -386.
  • 5Ikedma N, Nakajima Y, Tokuhara T,et al. Clinical significance of aminopetidase N/CD13 expression in human pancreatic car- cinoma[J]. Clin Cancer Res, 201)3,9(4) : 15(13): 1508.
  • 6Luo LM, Huang Y,Zhao BX,et al. Anti-tumor and anti-angiok genie effect of metronmoic cyclic NGR modified lippsomcs con- taining paclitaxel[J]. Biomaterials,2013,34(4) : 1102-1114.
  • 7Negussie AH , Miller JL, Reddy G, et al. Synthesis and in vitro evaluation of cyclic NGR peptide targeted thermally sensitive liposome[J]. J Control Release,2010,143(2) :265-273.
  • 8Xie Fir, Yao N, Qin Y,et al. Investigation of glucose modified liposomes using polyethylene glycols with different chain lengths as the linkers for brain targeting[J], lnt J Nanomedi cine,2012,7(2) : 163- 175.
  • 9Michael D,Jinzi Z, Joshua R,et al. APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes [J]. J Control Release, 2011,158 (1) : 298 -305.
  • 10Gao XL, Tao WX, Lu WX, et al. Lectin-conjugatcd PEOPLA nanoparticlcs :Preparation and brain delivery after intranasal administration [J]. Biomaterials, 2006,27(18) : 3482-3490.

同被引文献124

  • 1杨佳佳,韦世权,张科,陈妍,姜丰,周雪,肖婷,彭剑青,沈祥春,陶玲.香茅醇自乳化递送系统的制备及其体外抗肿瘤活性评价[J].中草药,2020,51(5):1196-1204. 被引量:2
  • 2赵欣.载microRNA-34a脂质体靶向治疗肺癌干细胞靶的研究[J].中国生化药物杂志,2014,34(1):68-71. 被引量:11
  • 3黄吉春,蔡华荣,江跃全.双功能RGD-TAT肽修饰脂质体的构建及其脑胶质瘤靶向性研究[J].中国生化药物杂志,2014,34(3):1-3. 被引量:5
  • 4曹纯洁.长循环脂质体的研究进展[J].药学实践杂志,2005,23(1):1-3. 被引量:22
  • 5陈军,平其能,蔡宝昌.9-硝基喜树碱复合磷脂脂质体的研究[c].中国药学会年会会议论文集,2006:1411-1420.
  • 6BERNACKI R J, PERA P, GAMBACORTA P, et al. In vitro antitumor activity of 9-nitrocamptothecin as a single agent and in combination with other antitumor drugs [J]. Ann N Y Aead Sci, 2000(922): 293-297.
  • 7AMORINO G P, HERCULES S K, MOHR P J, et al. Preclinical evaluation of the orally active camptothecin analog, RFS-2000(9-nitro-20(s)-camptothecin) as a radiation enhancer [J]. Int J Radiat Oneol Biol Phys, 2000, 47(20): 503-509.
  • 8HUNG C L, DONIGER J, PALINI A, et al. 9-Nitrocamptothecin inhibits periperal blood lymphocytes HIV-1 replication in human I-IIV-infection/AIDS therapy [J] 238-244. a potential alternative for J Med Virol, 2001, 64(3):.
  • 9CEH B, W1NTERHALTER M, FREDERIK P M, et al. Stealth liposomes: from theory to product [J]. Adv Drug Deliv Rew, 1997, 24(2/3): 75-87.
  • 10FATTEL L, CERUTI M, DOSIO F. From conventional to stealth liposomes: a new frontier in cancer chemotherapy [J]. Tumori, 2003, 89(3): 237-247.

引证文献11

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部